Novaliq GmbH

General information

Novaliq GmbH
Im Neuenheimer Feld 515
69120 Heidelberg, Baden-Württemberg
Germany

Contact person: Christian Roesky, Managing Director / Chief Executive Officer
Company main phone: +49 (6221) 502590
Company main fax: +49 (6221) 5025921
Website: https://www.novaliq.com

Year founded:	2007
Source of foundation:	Independent foundation

Corporate description / mission:
Novaliq GmbH is a pharmaceutical company focused on the development and commercialization of ocular therapeutics based on EyeSol® which is designed to unfold the full potential of eye care treatments. NOV03 and CyclASol® are the two late-stage development compounds of the company. Novaliq offers an industry-leading portfolio addressing today's unmet medical needs of millions of patients with eye diseases.

State of ownership: Private / independent
Headquarters: Yes

Categorization

Sector:

Biotechnology - Therapeutics and Diagnostics

Subsector:

Drug delivery

Primary therapeutic areas:

Diseases of the eye / ophthalmology

Business model:

Manufacturer
Out-licensing
R&D
Supplier / Distributor

Customer segments:

Other
Large biotech & big pharma
Small biotech

Distribution:

Direct (own sales force)

Summary Products / Services / Technologies

Number of Biotech Products

Pre-clinical:	7
Phase II:	1
Phase III:	3
On the market:	4

Description of products:
CyclASol®
NOV03
NovaTears®+Omega-3

Technology used:
EyeSol® technology

Collaborations & Clients

Partnering strategy / collaborations:
AFT Pharmaceuticals Ltd
Ursapharm, etc.